CTRC Annual Symposium

Welcome
Ian M. Thompson, MD, Director, Cancer Therapy & Research Center

8:45 – 10:45 a.m.

SESSION I: Drug Discovery Strategies
Chair: Bruce J. Nicholson, Ph.D., Co-Director of CIDD, Chair of Biochemistry

8:45 a.m.

Keynote Speaker
Stephen W. Fesik, PhD, Orrin H. Ingram II Chair in Cancer Research and Professor of Biochemistry, Pharmacology and Chemistry Vanderbilt University School of Medicine
Title: "Cancer Drug Discovery Using Fragment-Based Methods"
(Q&A to follow)

9:45 a.m.

Stanton McHardy, PhD, Director of Medicinal Chemistry Core, UTSA
Title: "Center for innovation in Drug Discovery, Medicinal Chemistry Core at UTSA; Capabilities, Progress and Programs"

10:00 a.m.

Matthew J. Hart, PhD, Assistant Professor, Research, Molecular Medicine Title:&qout;Novel soluble receptor fusions for anagonizing the tumor - and metastasis-promoting activities of TGF-beta in advanced breast and prostate cancer"

10:15 a.m.

Andrew Hinck, PhD, Professor, Biochemistry, UTHSCSA
Title: "Novel Soluble receptor fusions for antagonizing the tumor-and metastasis-promoting activities of TGF-beta in advanced breast and prostate cancer"

10:45 a.m.

Coffee Break

UTHSCSA students, fellows/post-doctorates, faculty and CTRC Shared Resource leaders are eligible to present posters (only students and fellows/post-doctorates are eligible for awards)

LUNCH

SESSION II: Drug Development Approaches
Chair: Steve Weitman, MD, Director IDD

Keynote Speaker
Donald W. Kufe, MD, Professor, Department of Medicine, Harvard Medical School; Leader, Translational Pharmacology and Early Therapeutic Trials Program, Dana-Farber/Harvard Cancer Center
Title: "MUC1 Heterodimeric Oncoprotein: Fundamental, Translational and Clinical Research"
(Q&A to follow)

Devalingam Mahalingam, MD, PhD, Assistant Professor/Clinical Hematology/Medical Oncology UTHSCSA
Title: "Clinical Application of Oncolytic Viral Therapies"

Alexander Pertsemlidis, PhD, Associate Professor of Pediatrics, Greehey Children's Cancer Research Institute, UTHSCSA
Title: "miRNAs as potential therapeutic targets and agents"